Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Summary

This study involves Vyxeos (CPX-351), a formulation of a fixed combination of the two anti-tumor drugs, cytarabine and daunorubicin that will be given as an infusion over 90 minutes. This study will use what is called a "liposome" injection. This is a special fat capsule (called a liposome) that surrounds the cytarabine and daunorubicin and protects the drugs from being eliminated/destroyed by the body.

Timeline

Start

2018-10-11

Primary completion

2021-06-07

Completion

2023-09-14

Drugs

Indications